Strong revenue growth masks loss: profitability deteriorated
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Reiterated mid-teens growth + profitability improvement guidance not being met in Q2. Crop Protection turned EBIT-negative. FDA timeline slipping, margin recovery conditional.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue grew 36% YoY to ₹434 Cr but company posted ₹6 Cr loss; profitability collapsed despite scale due to 100%+ raw material inflation and ₹20 Cr FDA remediation costs. Near-term margin recovery is contingent on FDA clearance (uncertain) and customer pass-through of input costs (not yet realized). Long-term catalysts (CDMO contract, Animal Health ambition) exist but require execution.
₹434.2 Cr
Revenue · +36.3% YoY₹-6.1 Cr
Reported PAT · −82.5% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹434 Cr with EBITDA ₹45 Cr, margin 10.3%
METQ2 delivered revenue ₹434.2 Cr, OPM 10.3%, PAT -6.1 Cr — revenue and OPM match but PAT shows loss
Substantial improvement in profitability expected; margins will recover
MISSQ2 FY27 PAT negative ₹6 Cr vs implicit Q2 FY26 loss ~₹34 Cr; H1 PAT negative ₹14 Cr. Company lost money despite 36% revenue growth
Pharma mid-teens growth H2; Animal Health INR400 Cr by FY30 ambition
OVERSTATEDPharma Q2 revenue ₹278 Cr (EBIT margin 4.6% vs prior ~13.7%), down from Q2 FY26 base; Animal Health timeframe FY30 is multi-year aspiration, not near-term committed
CDMO contract commercial launch FY27 end with progressive volume ramp; high-margin business
PartialDescribed as 'niche molecule' with 'contribution margin well in excess' of crop business; 2-2.5 year gestation from contract signature; no Q2 revenue impact visible
Crop Protection navigating elevated raw material and energy prices; passing increases to customers
OVERSTATEDQ2 EBIT negative ₹2 Cr, H1 EBIT negative ₹8 Cr, EBIT margin -2.5% in H1. Pass-through promised but not yet realized; segment remains margin-negative
Earnings quality
What changed since the last call
Profitability sharply deteriorated
DowngradeH1 PAT -₹14 Cr (loss) vs prior year implied profitability. FDA remediation cost ₹20 Cr is new structural drag; management claims prior guidance of profitability improvement but Q2 contradicts it.
Crop Protection turned structurally weak
DowngradeQ2 EBIT -₹2 Cr (margin -1.5%), H1 -₹8 Cr (margin -2.5%). Chinese dumping, high input costs, and weak demand are described as structural, not transient.
CDMO contract won, new revenue stream
UpgradeMulti-year European-based agrochemical customer contract signed. Commercial launch expected FY27 end. Described as 'high-margin' and potential ₹50-75 Cr annual revenue at peak. New catalyst not in prior guidance.
FDA Bangalore facility approved (Swissmedic)
NeutralSwissmedic certification received for Bangalore facility; supports global regulatory reach but U.S. FDA reinspection still pending and is the key unlock.
The Q&A
Analysts pressed hard on margin collapse: Aman Vora (Premier) highlighted 900bps EBIT margin compression on flat pharma revenue; Harshil Parekh (BTH) challenged Gabapentin pricing and patent expiry risk; Raghuram Kuchi (Bestpals) repeatedly probed FDA timeline and profitability recovery credibility. Management acknowledged headwinds but was vague on timing, citing 'geopolitical situation' and 'weather impacts' as wildcards.
Pharma margin collapse — Aman Vora, Premier Capital
AnsweredRaw material costs +100%, product mix, FDA remediation expenses ₹20 Cr/yr. Expect recovery H2 if input costs stabilize and pass-through happens.
Crop Protection segment outlook — Aman Vora, Premier Capital
PartialChinese competition depressing prices; volume and margin recovery expected H2 as inventory depletes and demand returns. Structural challenge but management optimistic.
Gabapentin price pressure — Harshil Parekh, BTH Capital
PartialPrice erosion from raw materials and customer cost pressure, not patent. Gabapentin is a flagship molecule; backward integration in Panoli protects margins.
FDA timeline and profitability — Raghuram Kuchi, Bestpals Research
PartialFace-to-face FDA meeting June 2026; confident on clearance. Multiple regulatory approvals already received (ANVISA Brazil, PMDA Japan, Swissmedic). Expect growth to return and margins improve to pre-2024 FY23 levels post-FDA.
CDMO contract commercial timeline — Henil Bagadia, Equicorp
PartialCommercial launch FY27 end with progressive volumes. Capacity currently 60-70% utilized due to quality control shutdowns. Expect 4-6 products from Bangalore, 6-7 if Panoli comes back. DMF filings have 3-5 year gestation.
Animal Health ₹400 Cr target — Raghuram Kuchi, Bestpals Research
AnsweredMultiple customers, risk-based approach. Pipeline and target established. Not dependent on single customer.
Crop protection recovery timeline — Henil Bagadia, Equicorp
PartialSlowdown due to weather, El Niño, high channel inventory post-COVID. Inventory now depleting and genuine demand returning. Volumes increasing, capacity utilization improving.
H2 profitability guidance — Aman Vora, Premier Capital
DodgedCannot quantify precisely, but conditional on FDA clearance progress, input cost stabilization, and customer pass-through. Expected to be 'well in excess of 17%, 18%' by FY27 end if war situation normalizes and FDA clears.
Guidance
FY27 mid-teens growth (reiterated from prior guidance)
MediumQ2 delivered 36% YoY but this is YoY comparison; full-year mid-teens would imply base-effect headwind H2. Pharma mid-teens H2 contingent on production ramp and FDA progress.
Substantial improvement in profitability; margins to recover to pre-2024 FY23 levels
LowQ2 delivered negative PAT and pharma EBIT margin 4.6% vs ~13.7% prior year. Recovery contingent on FDA clearance (uncertain timeline), input cost stabilization, and customer pass-through (not yet realized).
H2 profitability 'significantly better' than H1; EBITDA margins 17-18% by FY27 end (conditional)
LowManagement cited geopolitical uncertainty and war situation as wildcard; margins could be 100bps lower if war situation persists. FDA remediation ₹20 Cr continues.
Targeted capex aligned with long-term growth objectives; focus on high-return projects
High₹81 Cr in Q2 for derisking, regulatory upgrades, Panoli repurposing for Personal Care CDMO. Capacity expansion tied to secured contracts (CDMO).
Risks the call surfaced
Regulatory uncertainty
HighU.S. FDA reinspection expected FY27 end but timing uncertain. Profitability recovery and new pharma DMF approvals contingent on clearance. Delay of even 1-2 quarters could push margin recovery to FY28.
Input cost inflation
HighRaw material and solvent costs inflated >100% in some cases. Management claims majority of increases will be passed to customers over next quarters but pricing power is uncertain. If pass-through fails, margins remain under pressure.
Crop Protection structural decline
HighCrop Protection Q2 EBIT -₹2 Cr (margin -1.5%), H1 -₹8 Cr (margin -2.5%). Chinese competition, inventory buildup post-COVID, and weather impacts cited. If segment remains negative, it's a 36% drag on consolidated profitability.
Profitability negative despite scale
HighQ2 revenue ₹434 Cr (+36% YoY) but PAT -₹6 Cr (loss). H1 revenue ₹837 Cr but PAT -₹14 Cr (loss). Operating leverage is negative, suggesting structural cost base or mix issue not captured in prior guidance.
Customer concentration in Crop Protection
MediumCrop Protection customer base is concentrated among large accounts. If any large customer restructures supply chain or reduces volumes, revenue volatility could spike.
Management
Score 6/10. Clear on challenges (raw material inflation, FDA timeline, crop market dynamics) but vague on profitability recovery timeline. Acknowledged Q2 was loss but framed as 'improvement' vs prior year loss. Transparency on CDMO mechanics good; less transparent on pass-through assumption. Achieved 36% YoY revenue growth but profitability went backward (loss in Q2). Prior-quarter guidance of 'substantial improvement' not delivered. FDA timeline slipped; reinspection expected FY27 end, not earlier. CDMO contract secured but no revenue yet.
1 · FY27 end (by Mar 2027)
U.S. FDA reinspection clearance expected; unlocks margin recovery and new pharma DMF products
2 · FY27 end (by Mar 2027)
CDMO contract commercial launch with progressive volume ramp; niche high-margin agrochemical supply
3 · Q3 FY27 (Oct-Dec 2026)
Crop Protection volume recovery post-inventory depletion; margin pressure may ease if input costs stabilize
Long-term catalysts (CDMO contract, Animal Health ambition) exist but require execution.
Hikal Q2 FY27: consolidated loss narrows to ₹6.1 Cr YoY as revenue jumps 36%, OPM expands to 10.3%
PAT +82.5% YoY · revenue +36.3% · margins expanding
₹434.2 Cr
+36.3% YoY
₹-6.1 Cr
+82.5% YoY
-1.4%
+9.5pp YoY
₹-0.49
Hikal's consolidated Q2 FY27 revenue rose 36.3% YoY to ₹434.2 Cr (₹318.5 Cr) and 7.8% QoQ (₹402.8 Cr), while the net loss narrowed sharply to ₹6.1 Cr (EPS -₹0.49) from ₹34.9 Cr a year ago (EPS -₹2.83) and ₹7.4 Cr last quarter. It is the company's fifth consecutive loss-making quarter but by far the smallest, continuing the healing trend visible since Q1.
Q2 FY-2027 vs prior quarters
The improvement is pharma-led: Pharmaceuticals revenue grew 46.6% YoY to ₹277.8 Cr (19.1% QoQ) and the segment swung to a ₹12.8 Cr profit from a ₹17.5 Cr loss a year ago. Crop Protection revenue grew 21.2% YoY to ₹156.4 Cr but fell 7.7% QoQ (seasonal) and the segment stayed loss-making at ₹2.3 Cr, albeit narrower than -₹9.6 Cr a year ago and -₹6.0 Cr last quarter. Group operating margin (EBITDA ex-exceptional items / revenue) expanded to 10.3% from 2.3% YoY and NPM improved to -1.4% from -10.9%. On a QoQ basis reported OPM looks like it eased from 11.4%, but that prior figure included the ₹8.9 Cr one-off credit; stripped of it, Q1's underlying OPM was ~9.2%, so the sequential trend is also one of expansion to 10.3%.
The stock went into the print at ₹230.05, up 5.5% over the past month of trading.
FY27 revenue growth 14–16% with EBITDA growth 25–30%, driven by strong pharma (+18–19% CAGR) and marginal crop growth (mid-to-high single digit). Animal Health targeting ₹400Cr by FY30 at 20%+ EBITDA margins; Personal Care projected ₹200Cr by FY30 at >20% margins.
— This quarter: beat
Against management's August 2026 guidance of FY27 revenue growth of 14-16% and EBITDA growth of 25-30%, H1 FY27 is running well ahead: consolidated revenue is up 19.8% YoY to ₹837.0 Cr and EBITDA (ex-exceptional) is up roughly 154% YoY to ₹81.9 Cr from ₹32.3 Cr — a beat on pace, though the EBITDA comparison is flattered by a depressed FY26 H1 base, which this filing's note 8 ties to the Jigani facility's USFDA warning letter. Segment-level guidance also tracks: H1 Pharma revenue is up 30.3% YoY (guided +18-19% CAGR) and H1 Crop Protection is up 6.2% YoY (guided mid-to-high single digit). No analyst consensus for this specific quarter turned up in a pre-print search, and the company has not yet issued a separate investor press release for Q2, so this read rests on the filing's own disclosures. The print also lands against a governance backdrop — Jai Hiremath's October 1 exit as Executive Chairman and a new CEO appointment, a new multi-year global CDMO contract signed November 2, and Swissmedic GMP certification for the Bengaluru API site on October 30 — all just after quarter-end but relevant to how the pharma growth story is read into Q3.
W1
H2 FY27 execution against guided FY27 revenue growth of 14-16% and EBITDA growth of 25-30% — H1 is ahead but partly on a depressed FY26 base
W2
Crop Protection segment's return to profit — still loss-making at -₹2.3 Cr despite 21.2% YoY revenue growth
W3
Pharma recovery from the Jigani facility USFDA warning letter and execution on the new multi-year CDMO contract signed Nov 2, 2026
Filing in ₹ Million, converted to Crore (÷10). Standalone and consolidated are near-identical — the two subsidiaries (Acoris Research, Hikal LLC USA) are immaterial per auditor note 7. Q1 FY27 carried a ₹8.9 Cr one-off gratuity/labour-code credit (none this quarter), which flatters the QoQ OPM comparison. Note 8 flags ongoing Pharma sales impact from the Aug-2025 USFDA warning letter on the Jigani facility.
36% growth, ₹6 crore loss: Hikal's profitability promise stalls
Revenue surged to ₹434 crore, but the company posted a ₹6.1 crore loss—and profitability actually deteriorated from H1. Management reiterated mid-teens growth guidance while acknowledging 100%+ raw material inflation, ongoing FDA remediation costs, and a crop protection segment that turned loss-making. The tension between headline growth and operating leverage collapse defines this quarter.
₹434 Cr
+36% YoY, +7.8% QoQ
-₹6.1 Cr
Loss; H1 PAT -₹14 Cr
10.3%
Flat vs H1, compressed vs prior year
4.6%
vs 13.7% prior year: 900bps drop
The core tension: scale without leverage
Revenue accelerated 36% year-over-year to ₹434 crore, yet the company reported a ₹6.1 crore loss. This isn't a one-time item reconciliation—it's a deterioration in the cash profit frame. H1 PAT sits at -₹14 crore negative, a swing from prior year profitability. Operating margin at 10.3% is being crushed by cost of goods sold that's up faster than pricing power. The earnings call made clear why: raw material costs and solvents inflated over 100%, the company is still deep in FDA remediation expenses at ₹20 crore annually, and the crop protection segment—which carries 36% of revenue—turned sharply loss-making (Q2 EBIT -₹2 crore, H1 EBIT -₹8 crore).
Management's claims vs. what holds up
Q2 revenue ₹434 Cr with EBITDA ₹45 Cr, OPM 10.3%
SupportedDelivered: ₹434.2 Cr revenue, OPM 10.3%—numbers match
Substantial improvement in profitability expected; margins will recover
ContradictedQ2 PAT -₹6.1 Cr; H1 PAT -₹14 Cr. Company posted losses despite 36% revenue growth
Pharma mid-teens H2 growth; reiterated full-year mid-teens guidance
OverstatedPharma Q2 ₹278 Cr EBIT margin 4.6% vs ~13.7% prior year (900bps drop on near-flat volume). H2 contingent on FDA clearance by FY27 end
CDMO contract signed; commercial launch FY27 end with high-margin contribution
PartialContract secured but 2–2.5 year gestation timeline; no Q2 revenue yet. Launch 'FY27 end' is aspirational; actual ramp multi-quarter
Crop Protection navigating raw material inflation; customer pass-through underway
OverstatedQ2 EBIT -₹2 Cr (margin -1.5%), H1 EBIT -₹8 Cr (margin -2.5%). Segment loss-making; no pass-through evidence yet
What changed on this call
Bull-bear ledger
Revenue accelerated 36% YoY despite sector headwinds (crop, raw materials)
CDMO contract is a genuine new revenue stream with high-margin profile
Regulatory reach expanding (ANVISA Brazil, PMDA Japan, Swissmedic Europe)
Animal Health ₹400 Cr ambition by FY30 is multi-year growth lever
PAT negative ₹6.1 Cr in Q2 despite ₹434 Cr revenue—operating leverage is broken
Pharma EBIT margin collapsed 900bps YoY; raw material pass-through is assumed not assured
Crop Protection segment is now loss-making; Chinese dumping and weak demand structural
FDA remediation cost ₹20 Cr/yr ongoing through FY27; blocks profitability recovery
Guidance of 'substantial profitability improvement' reiterated but Q2 contradicts it
Risks ranked by how much they should concern a holder
FDA Bangalore reinspection delayed; blocks profitability recovery
HighExpected by FY27 end (March 2027) but no confirmed timeline. Each quarter of delay pushes margin recovery and new pharma DMF approvals into FY28. Profitability guidance credibility depends on this.
Raw material pass-through not yet realized; margin risk escalates
HighManagement assumes majority of 100%+ input cost increases will flow through to customers 'over next quarters,' but no evidence in Q2 pricing data. If pass-through fails or lags, margins stay compressed indefinitely.
Crop Protection segment structural, not cyclical; 36% of revenue at risk
HighQ2 and H1 both deeply negative (EBIT -₹2 Cr and -₹8 Cr respectively). Chinese competition and inventory overhang cited as 'structural.' If segment doesn't recover, it's a permanent ₹300+ Cr revenue base dragging on consolidated margins.
Profitability guidance reiterated despite Q2 loss contradicting it
MediumManagement claims 'substantial improvement' but delivered loss in Q2. Credibility grade 'C' on the call. If H2 doesn't deliver materially better PAT, guidance loses all weight.
Geopolitical and weather volatility (management's cited wildcard)
MediumManagement explicitly cited 'geopolitical situation' and 'weather impacts' as wildcards that could reduce H2 EBITDA margin guidance by 100bps. Uncontrollable tail risk.
How the street is positioning
The price action tells a different story than the fundamentals. The stock is at ₹222.63, up 52% off its 52-week low (₹146.25) but still -70% from its all-time high (₹742). Short-term momentum is bullish: the stock trades above its 20-day, 50-day, and 200-day moving averages (₹211.28, ₹216.52, and ₹204.10 respectively), and volume is increasing. RSI at 56.6 signals neutral momentum—not oversold, not overbought. This rally is likely a bounce off depressed valuations, not a fundamental revaluation.
But ownership flows tell the real story: FII shareholding has collapsed from 5.69% a year ago to 0.99% as of Q1 FY27—a systematic sell-off by a full 4.7 percentage points. DII ownership is stable at ~7%, and promoters hold steady at 68.85%. The foreign exodus suggests institutions have seen enough of the margin compression and profitability deterioration to exit at higher valuations. Bulk deals in early September (₹244–₹246 range) show balanced buying and selling, with no suspicious insider-linked selling. The September activity pre-dates the earnings miss, so it's not a tell.
The disconnect is stark: price action is rewarding the 36% revenue bump, but fundamentals show operating leverage has snapped. FII has already voted with its feet. A bounce off the 52-week low is natural, but the all-time high of ₹742 sits 70% above current levels—a reminder that Hikal was once valued for double-digit organic profit growth, not losses at scale.
1 · FDA Bangalore reinspection clearance timeline
The single most important unlock. Any indication that the reinspection will slip past March 2027 (FY27 end) is a 'downgrade to reduce' signal. Conversely, clearance by calendar Q4 2026 (before March) would validate H2 margin recovery.
2 · Raw material pass-through evidence in Q3 pricing
Look for revenue per unit growth in Q3 (October–December 2026) without corresponding volume gains. If pricing is flat or declining despite claimed pass-through, the margin recovery thesis is broken.
3 · Crop Protection EBIT turn positive
This is the non-negotiable proof point. If Crop Protection remains loss-making in Q3, it signals the segment is indeed structural and not a trough. If EBIT turns positive, the inventory-depletion thesis holds.
Hikal posted headline revenue growth that masks a profitability collapse. The company is profitable on paper only because EBITDA is positive; cash profit (PAT) is negative, FDA remediation costs are structural, and the crop protection business is a drag. Management reiterated guidance but Q2 results say the company missed on both revenue growth sustainability and profitability improvement.
Rating: Hold. The stock has bounced 52% off its low and trades above its moving averages, but FII outflows and the -70% drawdown from the all-time high are warnings. Until management demonstrates FDA clearance, raw material pass-through, and crop recovery in Q3 and Q4, this is a prove-it story, not a momentum play. The number to track from here: Q3 pharma EBIT margin—if it recovers toward 10%+ (away from Q2's 4.6%), the thesis holds. If it stays compressed, margins may not recover even if volume grows.